PPARγ and PPARGC1B polymorphisms modify the association between phthalate metabolites and breast cancer risk

Biomarkers. 2013 Sep;18(6):493-501. doi: 10.3109/1354750X.2013.816776. Epub 2013 Jul 18.

Abstract

Context: Breast cancer (BC) risk has been differentially associated with urinary levels of some phthalate metabolites.

Objective: To investigate whether PPARγ and PPARGC1B polymorphisms modulate these associations.

Materials and methods: 208 BC cases were age-matched with 220 population controls. Phthalate metabolites were determined by HPLC-MS. PPARγ Pro12Ala (rs1801281) and PPARGC1B Ala203Pro (rs7732671) and Val279Ile (rs17572019) were genotyped.

Results: The association between mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) and BC risk was positively modified in PPARγ Pro12Ala C carriers. The association with mono-iso-butyl phthalate (MiBP) in PPARGC1B Ala203Pro G carriers was negatively modified.

Conclusion: PPARγ and PPARGC1B polymorphisms modulate the association between phthalate exposure and BC risk.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms / genetics*
  • Breast Neoplasms / metabolism
  • Carrier Proteins / genetics*
  • Female
  • Genetic Predisposition to Disease*
  • Humans
  • PPAR gamma / genetics*
  • Phthalic Acids / metabolism*
  • Phthalic Acids / urine
  • Polymorphism, Single Nucleotide*
  • RNA-Binding Proteins

Substances

  • Carrier Proteins
  • PPAR gamma
  • PPARGC1B protein, human
  • Phthalic Acids
  • RNA-Binding Proteins